nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A7—Ifosfamide—testicular cancer	0.0891	0.18	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0891	0.18	CbGbCtD
Tacrolimus—CYP3A5—Ifosfamide—testicular cancer	0.0668	0.135	CbGbCtD
Tacrolimus—ABCB1—Dactinomycin—testicular cancer	0.0368	0.0746	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—testicular cancer	0.0319	0.0647	CbGbCtD
Tacrolimus—ALB—Methotrexate—testicular cancer	0.0263	0.0532	CbGbCtD
Tacrolimus—CYP3A4—Ifosfamide—testicular cancer	0.0261	0.0528	CbGbCtD
Tacrolimus—ABCB1—Vinblastine—testicular cancer	0.0231	0.0467	CbGbCtD
Tacrolimus—ABCB1—Cisplatin—testicular cancer	0.0212	0.0428	CbGbCtD
Tacrolimus—ABCB1—Etoposide—testicular cancer	0.0208	0.0421	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—testicular cancer	0.0142	0.0287	CbGbCtD
Tacrolimus—CYP3A4—Vinblastine—testicular cancer	0.0138	0.028	CbGbCtD
Tacrolimus—ABCB1—Methotrexate—testicular cancer	0.0137	0.0278	CbGbCtD
Tacrolimus—CYP3A4—Etoposide—testicular cancer	0.0125	0.0252	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—testicular cancer	0.00849	0.0172	CbGbCtD
Tacrolimus—ABCA5—seminal vesicle—testicular cancer	0.00759	0.106	CbGeAlD
Tacrolimus—ABCA5—gonad—testicular cancer	0.00549	0.0767	CbGeAlD
Tacrolimus—PPP3CA—seminal vesicle—testicular cancer	0.00513	0.0717	CbGeAlD
Tacrolimus—ABCA5—female gonad—testicular cancer	0.00446	0.0623	CbGeAlD
Tacrolimus—MTOR—embryo—testicular cancer	0.00403	0.0563	CbGeAlD
Tacrolimus—ABCA5—testis—testicular cancer	0.00395	0.0552	CbGeAlD
Tacrolimus—MTOR—seminal vesicle—testicular cancer	0.00379	0.0529	CbGeAlD
Tacrolimus—FKBP1A—seminal vesicle—testicular cancer	0.00341	0.0476	CbGeAlD
Tacrolimus—PPP3CA—female gonad—testicular cancer	0.00301	0.0421	CbGeAlD
Tacrolimus—ABCA5—lymph node—testicular cancer	0.00287	0.04	CbGeAlD
Tacrolimus—MTOR—gonad—testicular cancer	0.00274	0.0382	CbGeAlD
Tacrolimus—PPP3CA—testis—testicular cancer	0.00267	0.0373	CbGeAlD
Tacrolimus—FKBP1A—gonad—testicular cancer	0.00246	0.0344	CbGeAlD
Tacrolimus—MTOR—female gonad—testicular cancer	0.00222	0.0311	CbGeAlD
Tacrolimus—FKBP1A—female gonad—testicular cancer	0.002	0.028	CbGeAlD
Tacrolimus—MTOR—testis—testicular cancer	0.00197	0.0276	CbGeAlD
Tacrolimus—PPP3CA—BCR signaling pathway—BCL10—testicular cancer	0.00194	0.0456	CbGpPWpGaD
Tacrolimus—PPP3CA—lymph node—testicular cancer	0.00194	0.0271	CbGeAlD
Tacrolimus—FKBP1A—testis—testicular cancer	0.00177	0.0248	CbGeAlD
Tacrolimus—PPP3CA—C-MYB transcription factor network—MAD1L1—testicular cancer	0.00152	0.0358	CbGpPWpGaD
Tacrolimus—MTOR—lymph node—testicular cancer	0.00143	0.02	CbGeAlD
Tacrolimus—FKBP1A—lymph node—testicular cancer	0.00129	0.018	CbGeAlD
Tacrolimus—ALB—testis—testicular cancer	0.00122	0.017	CbGeAlD
Tacrolimus—MTOR—mTOR signalling—STK11—testicular cancer	0.00114	0.0268	CbGpPWpGaD
Tacrolimus—MTOR—PKB-mediated events—STK11—testicular cancer	0.00111	0.0261	CbGpPWpGaD
Tacrolimus—PPP3CA—C-MYB transcription factor network—H2AFZ—testicular cancer	0.00106	0.025	CbGpPWpGaD
Tacrolimus—ORM1—lymph node—testicular cancer	0.00101	0.0141	CbGeAlD
Tacrolimus—PPP3CA—C-MYB transcription factor network—KITLG—testicular cancer	0.000977	0.023	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000893	0.021	CbGpPWpGaD
Tacrolimus—ALB—lymph node—testicular cancer	0.000883	0.0123	CbGeAlD
Tacrolimus—CYP3A5—female gonad—testicular cancer	0.000871	0.0122	CbGeAlD
Tacrolimus—ABCB1—embryo—testicular cancer	0.000839	0.0117	CbGeAlD
Tacrolimus—ABCB1—seminal vesicle—testicular cancer	0.000788	0.011	CbGeAlD
Tacrolimus—MTOR—LKB1 signaling events—STK11—testicular cancer	0.000787	0.0185	CbGpPWpGaD
Tacrolimus—PPP3CA—C-MYB transcription factor network—KIT—testicular cancer	0.000667	0.0157	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000584	0.0137	CbGpPWpGaD
Tacrolimus—ABCB1—gonad—testicular cancer	0.00057	0.00796	CbGeAlD
Tacrolimus—MTOR—PI3K Cascade—STK11—testicular cancer	0.000545	0.0128	CbGpPWpGaD
Tacrolimus—MTOR—AMPK Signaling—STK11—testicular cancer	0.000539	0.0127	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000538	0.0127	CbGpPWpGaD
Tacrolimus—PPP3CA—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00048	0.0113	CbGpPWpGaD
Tacrolimus—ABCB1—female gonad—testicular cancer	0.000463	0.00647	CbGeAlD
Tacrolimus—MTOR—IRS-mediated signalling—STK11—testicular cancer	0.000456	0.0107	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—INSL3—testicular cancer	0.000453	0.0106	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.000445	0.0105	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events—STK11—testicular cancer	0.000444	0.0104	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00044	0.0103	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—STK11—testicular cancer	0.000428	0.0101	CbGpPWpGaD
Tacrolimus—MTOR—Insulin receptor signalling cascade—STK11—testicular cancer	0.000428	0.0101	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000424	0.00998	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.000418	0.00983	CbGpPWpGaD
Tacrolimus—ABCB1—testis—testicular cancer	0.00041	0.00574	CbGeAlD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.000408	0.00959	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.0004	0.0094	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.000389	0.00915	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—KITLG—testicular cancer	0.000377	0.00885	CbGpPWpGaD
Tacrolimus—MTOR—PI3K Cascade—FGFR3—testicular cancer	0.000375	0.00882	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—KITLG—testicular cancer	0.000368	0.00864	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000367	0.00863	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by Wnt—H2AFZ—testicular cancer	0.000367	0.00863	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—KITLG—testicular cancer	0.000365	0.00858	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—BCL10—testicular cancer	0.00036	0.00847	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.000356	0.00838	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—STK11—testicular cancer	0.000356	0.00836	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000348	0.00817	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—BCL10—testicular cancer	0.000347	0.00815	CbGpPWpGaD
Tacrolimus—MTOR—IRS-mediated signalling—FGFR3—testicular cancer	0.000314	0.00737	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.000311	0.00731	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events—FGFR3—testicular cancer	0.000305	0.00717	CbGpPWpGaD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.000302	0.00711	CbGpPWpGaD
Tacrolimus—ABCB1—lymph node—testicular cancer	0.000298	0.00416	CbGeAlD
Tacrolimus—MTOR—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000294	0.00692	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—FGFR3—testicular cancer	0.000294	0.00692	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.000288	0.00677	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.000285	0.00671	CbGpPWpGaD
Tacrolimus—CYP3A7—Biological oxidations—HPGDS—testicular cancer	0.000282	0.00663	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—KITLG—testicular cancer	0.000282	0.00662	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—FGFR3—testicular cancer	0.00028	0.00658	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—FGFR3—testicular cancer	0.000273	0.00642	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—FGFR3—testicular cancer	0.000271	0.00637	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000269	0.00633	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—INSL3—testicular cancer	0.000267	0.00629	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—KITLG—testicular cancer	0.000265	0.00623	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.000265	0.00623	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—KIT—testicular cancer	0.000257	0.00604	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—KITLG—testicular cancer	0.000253	0.00595	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—KITLG—testicular cancer	0.000252	0.00592	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—KIT—testicular cancer	0.000251	0.0059	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—KITLG—testicular cancer	0.000251	0.00589	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—KITLG—testicular cancer	0.00025	0.00587	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—KIT—testicular cancer	0.000249	0.00585	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000246	0.00578	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000245	0.00575	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000243	0.00572	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KITLG—testicular cancer	0.000235	0.00552	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000235	0.00552	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KITLG—testicular cancer	0.000235	0.00552	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—KITLG—testicular cancer	0.000233	0.00547	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000231	0.00542	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—KITLG—testicular cancer	0.00023	0.0054	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—KITLG—testicular cancer	0.000217	0.00511	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000209	0.00492	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—KITLG—testicular cancer	0.000209	0.00492	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000208	0.00489	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—INSL3—testicular cancer	0.000207	0.00487	CbGpPWpGaD
Tacrolimus—CYP3A5—Biological oxidations—HPGDS—testicular cancer	0.000204	0.00479	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—BCL10—testicular cancer	0.000202	0.00475	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.0002	0.00471	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—FGFR3—testicular cancer	0.000197	0.00463	CbGpPWpGaD
Tacrolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000193	0.00453	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—KIT—testicular cancer	0.000192	0.00452	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—FGFR3—testicular cancer	0.000188	0.00442	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—FGFR3—testicular cancer	0.000187	0.0044	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—FGFR3—testicular cancer	0.000186	0.00438	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—FGFR3—testicular cancer	0.000185	0.00436	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—H2AFZ—testicular cancer	0.000185	0.00436	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000184	0.00432	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000183	0.0043	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—KIT—testicular cancer	0.000181	0.00425	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000177	0.00415	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000174	0.0041	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—FGFR3—testicular cancer	0.000174	0.0041	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000174	0.0041	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—FGFR3—testicular cancer	0.000173	0.00406	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—KIT—testicular cancer	0.000173	0.00406	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—KIT—testicular cancer	0.000172	0.00404	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000171	0.00403	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—KIT—testicular cancer	0.000171	0.00402	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—FGFR3—testicular cancer	0.000171	0.00401	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—KIT—testicular cancer	0.00017	0.004	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000168	0.00394	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—FGFR3—testicular cancer	0.000161	0.0038	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KIT—testicular cancer	0.00016	0.00377	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00016	0.00377	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KIT—testicular cancer	0.00016	0.00377	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—KITLG—testicular cancer	0.00016	0.00376	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—KIT—testicular cancer	0.000159	0.00373	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000157	0.0037	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—KIT—testicular cancer	0.000157	0.00368	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—FGFR3—testicular cancer	0.000155	0.00365	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000155	0.00364	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000155	0.00363	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—BCL10—testicular cancer	0.000151	0.00356	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—KIT—testicular cancer	0.000148	0.00348	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—BCL10—testicular cancer	0.000145	0.00341	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—KIT—testicular cancer	0.000143	0.00335	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000142	0.00333	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000141	0.00332	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—H2AFZ—testicular cancer	0.000122	0.00287	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KITLG—testicular cancer	0.000122	0.00286	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—FGFR3—testicular cancer	0.000119	0.00279	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—INSL3—testicular cancer	0.000117	0.00274	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KITLG—testicular cancer	0.000112	0.00264	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—KIT—testicular cancer	0.000109	0.00256	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000103	0.00242	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—H2AFZ—testicular cancer	9.48e-05	0.00223	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—HPGDS—testicular cancer	9.48e-05	0.00223	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KITLG—testicular cancer	9.12e-05	0.00214	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—FGFR3—testicular cancer	9.05e-05	0.00213	CbGpPWpGaD
Tacrolimus—Oedema peripheral—Epirubicin—testicular cancer	8.87e-05	0.000226	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—testicular cancer	8.85e-05	0.000226	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—testicular cancer	8.85e-05	0.000226	CcSEcCtD
Tacrolimus—Urethral disorder—Epirubicin—testicular cancer	8.83e-05	0.000225	CcSEcCtD
Tacrolimus—MTOR—Immune System—BCL10—testicular cancer	8.81e-05	0.00207	CbGpPWpGaD
Tacrolimus—Hepatobiliary disease—Doxorubicin—testicular cancer	8.78e-05	0.000224	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—KITLG—testicular cancer	8.76e-05	0.00206	CbGpPWpGaD
Tacrolimus—Epistaxis—Doxorubicin—testicular cancer	8.76e-05	0.000223	CcSEcCtD
Tacrolimus—Angiopathy—Methotrexate—testicular cancer	8.73e-05	0.000223	CcSEcCtD
Tacrolimus—FKBP1A—Disease—KITLG—testicular cancer	8.72e-05	0.00205	CbGpPWpGaD
Tacrolimus—Sinusitis—Doxorubicin—testicular cancer	8.71e-05	0.000222	CcSEcCtD
Tacrolimus—Immune system disorder—Methotrexate—testicular cancer	8.69e-05	0.000222	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—testicular cancer	8.68e-05	0.000221	CcSEcCtD
Tacrolimus—Mediastinal disorder—Methotrexate—testicular cancer	8.67e-05	0.000221	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—testicular cancer	8.66e-05	0.000221	CcSEcCtD
Tacrolimus—Chills—Methotrexate—testicular cancer	8.64e-05	0.00022	CcSEcCtD
Tacrolimus—Nausea—Ifosfamide—testicular cancer	8.59e-05	0.000219	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—H2AFZ—testicular cancer	8.56e-05	0.00201	CbGpPWpGaD
Tacrolimus—Diarrhoea—Cisplatin—testicular cancer	8.53e-05	0.000218	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—testicular cancer	8.52e-05	0.000217	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—STK11—testicular cancer	8.51e-05	0.002	CbGpPWpGaD
Tacrolimus—Alopecia—Methotrexate—testicular cancer	8.51e-05	0.000217	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—testicular cancer	8.48e-05	0.000216	CcSEcCtD
Tacrolimus—Mental disorder—Methotrexate—testicular cancer	8.43e-05	0.000215	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—testicular cancer	8.42e-05	0.000215	CcSEcCtD
Tacrolimus—Hypersensitivity—Etoposide—testicular cancer	8.41e-05	0.000215	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—testicular cancer	8.4e-05	0.000214	CcSEcCtD
Tacrolimus—Erythema—Methotrexate—testicular cancer	8.38e-05	0.000214	CcSEcCtD
Tacrolimus—Malnutrition—Methotrexate—testicular cancer	8.38e-05	0.000214	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—testicular cancer	8.38e-05	0.000214	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—testicular cancer	8.36e-05	0.000213	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—testicular cancer	8.36e-05	0.000213	CcSEcCtD
Tacrolimus—PPP3CA—Disease—FGFR3—testicular cancer	8.36e-05	0.00196	CbGpPWpGaD
Tacrolimus—Rhinitis—Doxorubicin—testicular cancer	8.36e-05	0.000213	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—testicular cancer	8.33e-05	0.000213	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—testicular cancer	8.33e-05	0.000213	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—KIT—testicular cancer	8.31e-05	0.00195	CbGpPWpGaD
Tacrolimus—Hypoaesthesia—Doxorubicin—testicular cancer	8.29e-05	0.000212	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—testicular cancer	8.27e-05	0.000211	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—testicular cancer	8.23e-05	0.00021	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—testicular cancer	8.21e-05	0.000209	CcSEcCtD
Tacrolimus—Dysgeusia—Methotrexate—testicular cancer	8.21e-05	0.000209	CcSEcCtD
Tacrolimus—Asthenia—Etoposide—testicular cancer	8.19e-05	0.000209	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—testicular cancer	8.19e-05	0.000209	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—testicular cancer	8.17e-05	0.000208	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—testicular cancer	8.17e-05	0.000208	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—testicular cancer	8.14e-05	0.000208	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—testicular cancer	8.12e-05	0.000207	CcSEcCtD
Tacrolimus—Back pain—Methotrexate—testicular cancer	8.1e-05	0.000207	CcSEcCtD
Tacrolimus—Chills—Epirubicin—testicular cancer	8.08e-05	0.000206	CcSEcCtD
Tacrolimus—Pruritus—Etoposide—testicular cancer	8.08e-05	0.000206	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—testicular cancer	8.05e-05	0.000205	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—testicular cancer	8.03e-05	0.000205	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—testicular cancer	7.96e-05	0.000203	CcSEcCtD
Tacrolimus—Vomiting—Cisplatin—testicular cancer	7.92e-05	0.000202	CcSEcCtD
Tacrolimus—Vision blurred—Methotrexate—testicular cancer	7.9e-05	0.000201	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—testicular cancer	7.89e-05	0.000201	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—testicular cancer	7.88e-05	0.000201	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—KITLG—testicular cancer	7.88e-05	0.00185	CbGpPWpGaD
Tacrolimus—Rash—Cisplatin—testicular cancer	7.86e-05	0.0002	CcSEcCtD
Tacrolimus—Dermatitis—Cisplatin—testicular cancer	7.85e-05	0.0002	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—testicular cancer	7.84e-05	0.0002	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—testicular cancer	7.84e-05	0.0002	CcSEcCtD
Tacrolimus—Diarrhoea—Etoposide—testicular cancer	7.81e-05	0.000199	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—testicular cancer	7.79e-05	0.000199	CcSEcCtD
Tacrolimus—Ill-defined disorder—Methotrexate—testicular cancer	7.77e-05	0.000198	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—testicular cancer	7.77e-05	0.000198	CcSEcCtD
Tacrolimus—Anaemia—Methotrexate—testicular cancer	7.74e-05	0.000198	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—testicular cancer	7.74e-05	0.000197	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—testicular cancer	7.74e-05	0.000197	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—testicular cancer	7.73e-05	0.000197	CcSEcCtD
Tacrolimus—Tension—Epirubicin—testicular cancer	7.69e-05	0.000196	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—testicular cancer	7.68e-05	0.000196	CcSEcCtD
Tacrolimus—PPP3CA—Disease—KIT—testicular cancer	7.67e-05	0.0018	CbGpPWpGaD
Tacrolimus—Nervousness—Epirubicin—testicular cancer	7.62e-05	0.000194	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—testicular cancer	7.58e-05	0.000193	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—testicular cancer	7.56e-05	0.000193	CcSEcCtD
Tacrolimus—Malaise—Methotrexate—testicular cancer	7.56e-05	0.000193	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—testicular cancer	7.55e-05	0.000193	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—testicular cancer	7.54e-05	0.000192	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—testicular cancer	7.53e-05	0.000192	CcSEcCtD
Tacrolimus—Vertigo—Methotrexate—testicular cancer	7.53e-05	0.000192	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—testicular cancer	7.51e-05	0.000192	CcSEcCtD
Tacrolimus—Leukopenia—Methotrexate—testicular cancer	7.5e-05	0.000191	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—testicular cancer	7.48e-05	0.000191	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—testicular cancer	7.45e-05	0.00019	CcSEcCtD
Tacrolimus—Nausea—Cisplatin—testicular cancer	7.4e-05	0.000189	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—testicular cancer	7.39e-05	0.000189	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—testicular cancer	7.36e-05	0.000188	CcSEcCtD
Tacrolimus—Cough—Methotrexate—testicular cancer	7.31e-05	0.000187	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—testicular cancer	7.3e-05	0.000186	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—testicular cancer	7.28e-05	0.000186	CcSEcCtD
Tacrolimus—Convulsion—Methotrexate—testicular cancer	7.26e-05	0.000185	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—testicular cancer	7.26e-05	0.000185	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—testicular cancer	7.26e-05	0.000185	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—testicular cancer	7.26e-05	0.000185	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—testicular cancer	7.25e-05	0.000185	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—testicular cancer	7.21e-05	0.000184	CcSEcCtD
Tacrolimus—Rash—Etoposide—testicular cancer	7.2e-05	0.000184	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—testicular cancer	7.19e-05	0.000183	CcSEcCtD
Tacrolimus—Headache—Etoposide—testicular cancer	7.15e-05	0.000182	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—testicular cancer	7.15e-05	0.000182	CcSEcCtD
Tacrolimus—Arthralgia—Methotrexate—testicular cancer	7.13e-05	0.000182	CcSEcCtD
Tacrolimus—Myalgia—Methotrexate—testicular cancer	7.13e-05	0.000182	CcSEcCtD
Tacrolimus—Chest pain—Methotrexate—testicular cancer	7.13e-05	0.000182	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—testicular cancer	7.12e-05	0.000182	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—testicular cancer	7.1e-05	0.000181	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	7.08e-05	0.000181	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—testicular cancer	7.07e-05	0.00018	CcSEcCtD
Tacrolimus—Discomfort—Methotrexate—testicular cancer	7.05e-05	0.00018	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—testicular cancer	7.05e-05	0.00018	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—testicular cancer	7.04e-05	0.00018	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—testicular cancer	7.03e-05	0.000179	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—testicular cancer	7.02e-05	0.000179	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—testicular cancer	7.02e-05	0.000179	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—testicular cancer	6.98e-05	0.000178	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—testicular cancer	6.93e-05	0.000177	CcSEcCtD
Tacrolimus—Confusional state—Methotrexate—testicular cancer	6.9e-05	0.000176	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—testicular cancer	6.89e-05	0.000176	CcSEcCtD
Tacrolimus—Cough—Epirubicin—testicular cancer	6.84e-05	0.000175	CcSEcCtD
Tacrolimus—Anaphylactic shock—Methotrexate—testicular cancer	6.84e-05	0.000174	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—testicular cancer	6.84e-05	0.000174	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—testicular cancer	6.79e-05	0.000173	CcSEcCtD
Tacrolimus—Infection—Methotrexate—testicular cancer	6.79e-05	0.000173	CcSEcCtD
Tacrolimus—Nausea—Etoposide—testicular cancer	6.78e-05	0.000173	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—FGFR3—testicular cancer	6.78e-05	0.00159	CbGpPWpGaD
Tacrolimus—Hypertension—Epirubicin—testicular cancer	6.77e-05	0.000173	CcSEcCtD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.74e-05	0.00158	CbGpPWpGaD
Tacrolimus—Ill-defined disorder—Doxorubicin—testicular cancer	6.73e-05	0.000172	CcSEcCtD
Tacrolimus—Nervous system disorder—Methotrexate—testicular cancer	6.71e-05	0.000171	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—testicular cancer	6.71e-05	0.000171	CcSEcCtD
Tacrolimus—Thrombocytopenia—Methotrexate—testicular cancer	6.7e-05	0.000171	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—testicular cancer	6.68e-05	0.00017	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—testicular cancer	6.68e-05	0.00017	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—testicular cancer	6.68e-05	0.00017	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—testicular cancer	6.67e-05	0.00017	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—testicular cancer	6.65e-05	0.00017	CcSEcCtD
Tacrolimus—Skin disorder—Methotrexate—testicular cancer	6.64e-05	0.000169	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—H2AFZ—testicular cancer	6.64e-05	0.00156	CbGpPWpGaD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	6.63e-05	0.000169	CcSEcCtD
Tacrolimus—Hyperhidrosis—Methotrexate—testicular cancer	6.61e-05	0.000169	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—STK11—testicular cancer	6.6e-05	0.00155	CbGpPWpGaD
Tacrolimus—Discomfort—Epirubicin—testicular cancer	6.6e-05	0.000168	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—testicular cancer	6.54e-05	0.000167	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—testicular cancer	6.53e-05	0.000167	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—testicular cancer	6.52e-05	0.000166	CcSEcCtD
Tacrolimus—Anorexia—Methotrexate—testicular cancer	6.52e-05	0.000166	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—FGFR3—testicular cancer	6.51e-05	0.00153	CbGpPWpGaD
Tacrolimus—Syncope—Doxorubicin—testicular cancer	6.51e-05	0.000166	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—testicular cancer	6.49e-05	0.000166	CcSEcCtD
Tacrolimus—FKBP1A—Disease—FGFR3—testicular cancer	6.48e-05	0.00152	CbGpPWpGaD
Tacrolimus—Confusional state—Epirubicin—testicular cancer	6.45e-05	0.000165	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—testicular cancer	6.41e-05	0.000164	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—testicular cancer	6.4e-05	0.000163	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—testicular cancer	6.4e-05	0.000163	CcSEcCtD
Tacrolimus—Hypotension—Methotrexate—testicular cancer	6.39e-05	0.000163	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—testicular cancer	6.38e-05	0.000163	CcSEcCtD
Tacrolimus—Infection—Epirubicin—testicular cancer	6.36e-05	0.000162	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—testicular cancer	6.33e-05	0.000162	CcSEcCtD
Tacrolimus—Shock—Epirubicin—testicular cancer	6.3e-05	0.000161	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—testicular cancer	6.29e-05	0.00016	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—testicular cancer	6.28e-05	0.00016	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—testicular cancer	6.27e-05	0.00016	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—testicular cancer	6.26e-05	0.00016	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—testicular cancer	6.25e-05	0.000159	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Methotrexate—testicular cancer	6.23e-05	0.000159	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—KIT—testicular cancer	6.22e-05	0.00146	CbGpPWpGaD
Tacrolimus—Skin disorder—Epirubicin—testicular cancer	6.22e-05	0.000159	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—testicular cancer	6.19e-05	0.000158	CcSEcCtD
Tacrolimus—Insomnia—Methotrexate—testicular cancer	6.18e-05	0.000158	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—testicular cancer	6.18e-05	0.000158	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—testicular cancer	6.18e-05	0.000158	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—testicular cancer	6.18e-05	0.000158	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—testicular cancer	6.16e-05	0.000157	CcSEcCtD
Tacrolimus—Paraesthesia—Methotrexate—testicular cancer	6.14e-05	0.000157	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	6.13e-05	0.000156	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—KITLG—testicular cancer	6.11e-05	0.00144	CbGpPWpGaD
Tacrolimus—Discomfort—Doxorubicin—testicular cancer	6.1e-05	0.000156	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—testicular cancer	6.1e-05	0.000156	CcSEcCtD
Tacrolimus—Dyspnoea—Methotrexate—testicular cancer	6.1e-05	0.000156	CcSEcCtD
Tacrolimus—Somnolence—Methotrexate—testicular cancer	6.08e-05	0.000155	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—testicular cancer	6.04e-05	0.000154	CcSEcCtD
Tacrolimus—Dyspepsia—Methotrexate—testicular cancer	6.02e-05	0.000154	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—testicular cancer	5.98e-05	0.000153	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—KIT—testicular cancer	5.98e-05	0.0014	CbGpPWpGaD
Tacrolimus—Confusional state—Doxorubicin—testicular cancer	5.97e-05	0.000152	CcSEcCtD
Tacrolimus—FKBP1A—Disease—KIT—testicular cancer	5.95e-05	0.0014	CbGpPWpGaD
Tacrolimus—Decreased appetite—Methotrexate—testicular cancer	5.94e-05	0.000152	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—testicular cancer	5.92e-05	0.000151	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—testicular cancer	5.92e-05	0.000151	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Methotrexate—testicular cancer	5.9e-05	0.000151	CcSEcCtD
Tacrolimus—Fatigue—Methotrexate—testicular cancer	5.9e-05	0.00015	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—testicular cancer	5.88e-05	0.00015	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—FGFR3—testicular cancer	5.85e-05	0.00138	CbGpPWpGaD
Tacrolimus—Pain—Methotrexate—testicular cancer	5.85e-05	0.000149	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—testicular cancer	5.83e-05	0.000149	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—testicular cancer	5.83e-05	0.000149	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—testicular cancer	5.81e-05	0.000148	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—testicular cancer	5.8e-05	0.000148	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—testicular cancer	5.79e-05	0.000148	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—testicular cancer	5.78e-05	0.000147	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—testicular cancer	5.75e-05	0.000147	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—testicular cancer	5.75e-05	0.000147	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—testicular cancer	5.72e-05	0.000146	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—testicular cancer	5.71e-05	0.000146	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—testicular cancer	5.69e-05	0.000145	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—testicular cancer	5.64e-05	0.000144	CcSEcCtD
Tacrolimus—Feeling abnormal—Methotrexate—testicular cancer	5.64e-05	0.000144	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—testicular cancer	5.63e-05	0.000144	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Methotrexate—testicular cancer	5.59e-05	0.000143	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—testicular cancer	5.56e-05	0.000142	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—testicular cancer	5.53e-05	0.000141	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—testicular cancer	5.52e-05	0.000141	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—testicular cancer	5.52e-05	0.000141	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—testicular cancer	5.47e-05	0.00014	CcSEcCtD
Tacrolimus—Pain—Epirubicin—testicular cancer	5.47e-05	0.00014	CcSEcCtD
Tacrolimus—Urticaria—Methotrexate—testicular cancer	5.43e-05	0.000139	CcSEcCtD
Tacrolimus—Abdominal pain—Methotrexate—testicular cancer	5.41e-05	0.000138	CcSEcCtD
Tacrolimus—Body temperature increased—Methotrexate—testicular cancer	5.41e-05	0.000138	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—testicular cancer	5.39e-05	0.000138	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—KIT—testicular cancer	5.37e-05	0.00126	CbGpPWpGaD
Tacrolimus—Insomnia—Doxorubicin—testicular cancer	5.36e-05	0.000137	CcSEcCtD
Tacrolimus—MTOR—Disease—H2AFZ—testicular cancer	5.33e-05	0.00125	CbGpPWpGaD
Tacrolimus—Paraesthesia—Doxorubicin—testicular cancer	5.32e-05	0.000136	CcSEcCtD
Tacrolimus—MTOR—Immune System—KITLG—testicular cancer	5.31e-05	0.00125	CbGpPWpGaD
Tacrolimus—Dyspnoea—Doxorubicin—testicular cancer	5.28e-05	0.000135	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—testicular cancer	5.27e-05	0.000135	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—testicular cancer	5.26e-05	0.000134	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—testicular cancer	5.23e-05	0.000133	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—testicular cancer	5.21e-05	0.000133	CcSEcCtD
Tacrolimus—Decreased appetite—Doxorubicin—testicular cancer	5.15e-05	0.000131	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—testicular cancer	5.11e-05	0.00013	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—testicular cancer	5.11e-05	0.00013	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—testicular cancer	5.08e-05	0.00013	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—testicular cancer	5.06e-05	0.000129	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—testicular cancer	5.06e-05	0.000129	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—testicular cancer	5.06e-05	0.000129	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—testicular cancer	5.06e-05	0.000129	CcSEcCtD
Tacrolimus—Hypersensitivity—Methotrexate—testicular cancer	5.04e-05	0.000129	CcSEcCtD
Tacrolimus—Asthenia—Methotrexate—testicular cancer	4.91e-05	0.000125	CcSEcCtD
Tacrolimus—MTOR—Disease—KITLG—testicular cancer	4.9e-05	0.00115	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Doxorubicin—testicular cancer	4.88e-05	0.000124	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—testicular cancer	4.84e-05	0.000124	CcSEcCtD
Tacrolimus—Pruritus—Methotrexate—testicular cancer	4.84e-05	0.000123	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—HPGDS—testicular cancer	4.82e-05	0.00113	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Epirubicin—testicular cancer	4.71e-05	0.00012	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—testicular cancer	4.7e-05	0.00012	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—testicular cancer	4.68e-05	0.000119	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—testicular cancer	4.68e-05	0.000119	CcSEcCtD
Tacrolimus—Diarrhoea—Methotrexate—testicular cancer	4.68e-05	0.000119	CcSEcCtD
Tacrolimus—Asthenia—Epirubicin—testicular cancer	4.59e-05	0.000117	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—FGFR3—testicular cancer	4.54e-05	0.00107	CbGpPWpGaD
Tacrolimus—Pruritus—Epirubicin—testicular cancer	4.53e-05	0.000115	CcSEcCtD
Tacrolimus—Dizziness—Methotrexate—testicular cancer	4.52e-05	0.000115	CcSEcCtD
Tacrolimus—Diarrhoea—Epirubicin—testicular cancer	4.38e-05	0.000112	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—testicular cancer	4.36e-05	0.000111	CcSEcCtD
Tacrolimus—Vomiting—Methotrexate—testicular cancer	4.35e-05	0.000111	CcSEcCtD
Tacrolimus—Rash—Methotrexate—testicular cancer	4.31e-05	0.00011	CcSEcCtD
Tacrolimus—Dermatitis—Methotrexate—testicular cancer	4.31e-05	0.00011	CcSEcCtD
Tacrolimus—Headache—Methotrexate—testicular cancer	4.28e-05	0.000109	CcSEcCtD
Tacrolimus—Asthenia—Doxorubicin—testicular cancer	4.25e-05	0.000108	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—testicular cancer	4.23e-05	0.000108	CcSEcCtD
Tacrolimus—Pruritus—Doxorubicin—testicular cancer	4.19e-05	0.000107	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—KIT—testicular cancer	4.17e-05	0.00098	CbGpPWpGaD
Tacrolimus—Vomiting—Epirubicin—testicular cancer	4.07e-05	0.000104	CcSEcCtD
Tacrolimus—Nausea—Methotrexate—testicular cancer	4.06e-05	0.000104	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—testicular cancer	4.05e-05	0.000103	CcSEcCtD
Tacrolimus—Rash—Epirubicin—testicular cancer	4.03e-05	0.000103	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—testicular cancer	4.03e-05	0.000103	CcSEcCtD
Tacrolimus—Headache—Epirubicin—testicular cancer	4.01e-05	0.000102	CcSEcCtD
Tacrolimus—MTOR—Immune System—FGFR3—testicular cancer	3.95e-05	0.000928	CbGpPWpGaD
Tacrolimus—Dizziness—Doxorubicin—testicular cancer	3.92e-05	9.99e-05	CcSEcCtD
Tacrolimus—Nausea—Epirubicin—testicular cancer	3.8e-05	9.7e-05	CcSEcCtD
Tacrolimus—Vomiting—Doxorubicin—testicular cancer	3.76e-05	9.6e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—H2AFZ—testicular cancer	3.73e-05	0.000878	CbGpPWpGaD
Tacrolimus—Rash—Doxorubicin—testicular cancer	3.73e-05	9.52e-05	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—testicular cancer	3.73e-05	9.52e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—STK11—testicular cancer	3.71e-05	0.000873	CbGpPWpGaD
Tacrolimus—Headache—Doxorubicin—testicular cancer	3.71e-05	9.46e-05	CcSEcCtD
Tacrolimus—MTOR—Disease—FGFR3—testicular cancer	3.65e-05	0.000857	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KIT—testicular cancer	3.63e-05	0.000852	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—testicular cancer	3.52e-05	8.97e-05	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—STK11—testicular cancer	3.5e-05	0.000824	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HPGDS—testicular cancer	3.49e-05	0.000819	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KITLG—testicular cancer	3.43e-05	0.000807	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KIT—testicular cancer	3.35e-05	0.000787	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HPGDS—testicular cancer	3e-05	0.000706	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HPGDS—testicular cancer	2.63e-05	0.000618	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—FGFR3—testicular cancer	2.55e-05	0.0006	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—STK11—testicular cancer	2.53e-05	0.000595	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KIT—testicular cancer	2.34e-05	0.000551	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—STK11—testicular cancer	2.18e-05	0.000513	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—STK11—testicular cancer	1.91e-05	0.000449	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HPGDS—testicular cancer	1.62e-05	0.000381	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—STK11—testicular cancer	1.18e-05	0.000277	CbGpPWpGaD
